Zandoriah
Teriparatide biosimilar developed by CinnaGen. Reference product Forsteo (Forteo in the United States).
Brands by market: Zandoriah (EU) · Commercial partner or holder: CinnaGen
FDAnot listed
EMAApr 2026authorised
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Zandoriah
European Medicines Agency and European CommissionApprovedBrand
Zandoriah
Holder or applicant
CinnaGen Co Unipessoal LDA
Pathway
Centralised (Article 10(4))
Approved
Apr 2026
Application or permission
EMEA/H/C/006688
Presentations
see SmPC
Note
An earlier application, Teriparatide Cinnagen, was withdrawn.
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMAApr 2026Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.